Pulmonary Arterial Hypertension - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 266
Inquire Before Buying

Pulmonary Arterial Hypertension - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 9, 20, 39, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Pulmonary Arterial Hypertension - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
Introduction 5
Pulmonary Arterial Hypertension - Overview 6
Pulmonary Arterial Hypertension - Therapeutics Development 7
Pulmonary Arterial Hypertension - Therapeutics Assessment 20
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 32
Pulmonary Arterial Hypertension - Drug Profiles 55
Pulmonary Arterial Hypertension - Dormant Projects 244
Pulmonary Arterial Hypertension - Discontinued Products 246
Pulmonary Arterial Hypertension - Product Development Milestones 247
Appendix 256

List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H2 2017
Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Biogen Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Company, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Capricor Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Complexa Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Insys Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Nissan Chemical Industries Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Polyphor Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Savara Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H2 2017
Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Vicore Pharma AB, H2 2017
Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H2 2017
Pulmonary Arterial Hypertension - Dormant Projects, H2 2017
Pulmonary Arterial Hypertension - Dormant Projects, H2 2017 (Contd..1), H2 2017
Pulmonary Arterial Hypertension - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
  • Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size, Status and Forecast 2022
    Published: 19-Sep-2017        Price: US 3300 Onwards        Pages: 99
    This report studies the global Pulmonary Arterial Hypertension (PAH) Medicine market, analyzes and researches the Pulmonary Arterial Hypertension (PAH) Medicine development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - Gilead Sciences - Eli Lilly - Actelion Pharmaceuticals - United Therapeutics Corporation - ... Market segment by Re......
  • Global Nimodipine Market Professional Survey Report 2017
    Published: 07-Sep-2017        Price: US 3500 Onwards        Pages: 101
    This report studies Nimodipine in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Sun Pharm Inds - Heritage Pharms - Bionpharma - Arbor Pharms - The......
  • Global Pulmonary Arterial Hypertension (PAH) Drugs Market Professional Survey Report 2017
    Published: 05-Sep-2017        Price: US 3500 Onwards        Pages: 113
    This report studies Pulmonary Arterial Hypertension (PAH) Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Actelion Pharmaceuticals - DAIICHI SANKYO - Gla......
  • Global Hypertension Partnering 2010 to 2017
    Published: 01-Sep-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understandi......
  • United States Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017
    Published: 17-Aug-2017        Price: US 3800 Onwards        Pages: 107
    In this report, the United States Pulmonary Arterial Hypertension (PAH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), mark......
  • United States Nimodipine Market Report 2017
    Published: 15-Aug-2017        Price: US 3800 Onwards        Pages: 96
    In this report, the United States Nimodipine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Nimodipine in......
  • Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Report 2017
    Published: 11-Aug-2017        Price: US 4000 Onwards        Pages: 118
    In this report, the global Pulmonary Arterial Hypertension (PAH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units) , revenue (Million USD) , market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs for these regions, from 2012 to 2022 (forecast) , covering - Unite......
  • Global Nimodipine Sales Market Report 2017
    Published: 10-Aug-2017        Price: US 4000 Onwards        Pages: 104
    In this report, the global Nimodipine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Nimodipine for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - South......
  • Global Pulmonary Arterial Hypertension (PAH) Drugs Market Research Report 2017
    Published: 07-Aug-2017        Price: US 2900 Onwards        Pages: 118
    In this report, the global Pulmonary Arterial Hypertension (PAH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs in these regions, from 2012 to 2022 (forecast), covering - N......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs